Difference between revisions of "Plerixafor (Mozobil)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: <ref name="insert">[http://www.mozobil.com/document/Package_Insert.pdf Plerixafor (Mozobil) package insert]</ref><ref>[http://hemonc.org/...") |
Warner-admin (talk | contribs) m (Text replacement - "http://hemonc.org" to "https://hemonc.org") |
||
| (16 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: <ref name="insert">[http://www.mozobil.com/document/Package_Insert.pdf Plerixafor (Mozobil) package insert]</ref><ref>[ | + | Class/mechanism: Mobilizes hematopoetic stem cells by inhibiting the CXCR4 chemokine receptor and blocking its cognate ligand, stromal cell-derived factor-1α (SDF-1α). One function of CXCR4 is to anchor stem cells to the marrow matrix via SDF-1α or other adhesion molecules.<ref name="insert">[http://www.mozobil.com/document/Package_Insert.pdf Plerixafor (Mozobil) package insert]</ref><ref>[https://hemonc.org/docs/packageinsert/plerixafor.pdf Plerixafor (Mozobil) package insert (locally hosted backup)]</ref> |
| − | <br>Route: | + | <br>Route: SC |
| − | <br>Extravasation: | + | <br>Extravasation: n/a |
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[WHIM syndrome]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://www.uptodate.com/contents/ | + | *[http://www.uptodate.com/contents/plerixafor-patient-drug-information Plerixafor (Mozobil) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/plerixafor-patient-drug-information Plerixafor (Mozobil) patient drug information (UpToDate)]</ref> |
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *2009-07-30: Initial authorization | ||
| + | ==History of changes in PMDA indications== | ||
| + | *2016-12-19: Initial approval for the enhancement of mobilization of hematopoietic stem cells to the peripheral blood for autologous peripheral blood stem cell transplantation. | ||
| + | ==Also known as== | ||
| + | *'''Code name:''' AMD-3100 | ||
| + | *'''Brand name:''' Mozobil | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Subcutaneous medications]] | ||
| + | |||
| + | [[Category:CXCR4 inhibitors]] | ||
| + | |||
| + | [[Category:WHIM syndrome medications]] | ||
| + | |||
| + | [[Category:FDA approved in 2008]] | ||
| + | [[Category:EMA approved in 2009]] | ||
| + | [[Category:PMDA approved in 2016]] | ||
Latest revision as of 19:32, 23 June 2024
General information
Class/mechanism: Mobilizes hematopoetic stem cells by inhibiting the CXCR4 chemokine receptor and blocking its cognate ligand, stromal cell-derived factor-1α (SDF-1α). One function of CXCR4 is to anchor stem cells to the marrow matrix via SDF-1α or other adhesion molecules.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in EMA indication
- 2009-07-30: Initial authorization
History of changes in PMDA indications
- 2016-12-19: Initial approval for the enhancement of mobilization of hematopoietic stem cells to the peripheral blood for autologous peripheral blood stem cell transplantation.
Also known as
- Code name: AMD-3100
- Brand name: Mozobil